BSE · 531726 · Pharmaceuticals
Panchsheel Organics Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹110 Cr with net profit ₹14 Cr — a 12.51% net margin, versus 13.1% the period before.
Shareholding
As of 2026-06-30
- Promoter56.12%
- Public43.88%
7,966 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.79× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #16 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,43,116 Cr | 81.6 | 14.57 | 15.32% | 26.05% |
| Neuland Laboratories Ltd. | ₹29,028 Cr | 58.31 | 15.51 | 19.42% | 20.99% |
| Acutaas Chemicals Limited | ₹27,383 Cr | 70.91 | 16.55 | 21.54% | 26.42% |
| Jubilant Pharmova Ltd. | ₹15,968 Cr | 41.15 | 2.25 | 5.62% | 4.11% |
| Aarti Drugs Ltd. | ₹3,873 Cr | 20.1 | 2.5 | 12.58% | 7.14% |
| SMS Pharmaceuticals Ltd. | ₹3,774 Cr | 36.87 | 4.82 | 12.98% | 11.41% |
| Hikal Limited | ₹2,767 Cr | 65.23 | 2.31 | 3.03% | -1.96% |
| Beta Drugs Limited | ₹2,289 Cr | 50.22 | 9.32 | 16.95% | 11.11% |
| NGL Fine Chem Limited | ₹1,652 Cr | 28.89 | 5.03 | 14.62% | 10.67% |
| Fermenta Biotech Ltd. | ₹1,383 Cr | 25.27 | 3.39 | 17.67% | 11.68% |
| Panchsheel Organics Ltd.(this company) | ₹141 Cr | 13.68 | 0.99 | 7.69% | 9.56% |
AI analysis
AI-generated · google/gemini-2.5-flashPanchsheel Organics Ltd. has a market capitalization of Rs 154 Cr. The company reported revenue of Rs 110.25 Cr and a profit margin of 10.16%. Its EPS is Rs 8.22, with a Price-to-Earnings (PE) ratio of 90.5. The book value is Rs 106.92. Return on equity (ROE) stands at 7.69% and Return on Capital Employed (ROCE) is 9.73%. The company's debt-to-equity ratio is 0.05. Promoter holding is 56.12%, while public holding is 43.88% as of June 30, 2026.
Positives
- +The company's debt-to-equity ratio is low at 0.05.
- +Promoter holding is stable at 56.12% with no shares pledged.
- +Revenue has grown from Rs 49.67 Cr in Mar 2021 to Rs 110.25 Cr in Mar 2025.
Negatives
- −The Price-to-Earnings (PE) ratio is 90.5.
- −Quarterly net profit decreased from Rs 3.68 Cr in Dec 2025 to Rs 1.7 Cr in Mar 2026.
- −Annual EPS declined from Rs 10.71 in Mar 2024 to Rs 10.47 in Mar 2025.
- −The dividend yield is high at 68%, which may be unsustainable.
- −No quarterly EPS data is available in the provided dataset.
Financial Performance
Panchsheel Organics Ltd. has shown fluctuating annual revenue. Revenue increased from Rs 49.67 Cr in Mar 2021 to Rs 110.25 Cr in Mar 2025. Net profit also rose from Rs 5.01 Cr in Mar 2021 to Rs 13.79 Cr in Mar 2025. However, there was a decline in net profit to Rs 1.7 Cr in March 2026 from Rs 3.68 Cr in December 2025.
Profitability & Returns
The company's profitability, as indicated by its profit margin, is 10.16%. Return on Equity (ROE) is reported at 7.69%, and Return on Capital Employed (ROCE) at 9.73%. Annual EPS saw a decline from Rs 10.71 in Mar 2024 to Rs 10.47 in Mar 2025.
Balance Sheet
Panchsheel Organics Ltd. maintains a low debt-to-equity ratio of 0.05, suggesting limited reliance on borrowed capital. The book value per share is Rs 106.92.
Ownership & Pledges
As of June 30, 2026, promoter holding in Panchsheel Organics Ltd. is 56.12%. There are no shares pledged by the promoters, indicating financial stability regarding promoter holdings.
Data as of — price: 2026-09-17 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.